Immunogenicity and Safety of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu) in Adults and Elderly in Korea.

Trial Profile

Immunogenicity and Safety of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu) in Adults and Elderly in Korea.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Jan 2014

At a glance

  • Drugs Influenza virus vaccine (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 14 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top